keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lanreotide (BIM 23014) diTFA, a somatostatin analogue, exhibits antineoplastic activity and may be utilized in carcinoid syndrome research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Lanreotide (BIM 23014) diTFA, a somatostatin analogue, exhibits antineoplastic activity and may be utilized in carcinoid syndrome research [1] [2]. |
In vitro | Lanreotide (BIM 23014) at 100 nM concentration, increased apoptosis when combined with radiation over a period of 0 to 48 hours [1]. |
In vivo | Lanreotide administered subcutaneously at dosages ranging from 2.5 to 10 mg/kg daily for five consecutive days leads to the inhibition of tumor growth [1]. |
Synonyms | BIM 23014 diTFA |
Molecular Weight | 1324.37 |
Formula | C58H71F6N11O14S2 |
CAS No. | 1024499-83-9 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lanreotide diTFA 1024499-83-9 BIM 23014 diTFA inhibitor inhibit